RBC Capital has maintained its Sector Perform rating on SolarEdge Technologies (NASDAQ: NASDAQ:SEDG) but reduced the price target to $25.00 from the previous $35.00.
The adjustment follows a revision of the company's 2025 and 2026 financial estimates, taking into account a more conservative outlook on demand and adjusted selling price (ASP) assumptions.
The RBC analyst noted that while SolarEdge could benefit from its positioning with installers in the growing market for third-party ownership (TPO) models, it may face competitive challenges in the short term.
This is particularly pertinent as Tesla (NASDAQ:TSLA)'s Powerwall 3 could see increased adoption, potentially outpacing SolarEdge's efforts to scale up domestic production of its own battery storage solutions.
SolarEdge's stock price target has been influenced by a variety of factors, including market share projections and product adoption rates. The company's strategic position with installers for TPO adoption is a positive indicator, yet the forecast acknowledges the possibility of Tesla's Powerwall 3 impacting SolarEdge's market presence before it can fully scale its battery production.
In summary, RBC Capital has revised its expectations for SolarEdge, citing a cautious demand outlook and changes in ASP assumptions. The firm has lowered the price target to $25, maintaining a Sector Perform rating, as SolarEdge navigates the competitive landscape and works to ramp up its battery production capabilities.
In other recent news, SolarEdge Technologies has been the subject of multiple analyst adjustments. The company's price target was significantly reduced by GLJ Research, which maintains a Sell rating on the stock. This comes on the back of a revised forecast for SolarEdge's fiscal year 2028 EBITDA, which is estimated at $9.3 million.
Morgan Stanley also reduced its price target for the company due to slower expected revenue growth and narrower margins, while maintaining an Equalweight rating. The company has reported second-quarter revenues of approximately $265 million and aims for a revenue target of $550 million for the second quarter of 2025.
In the midst of these financial projections, Jefferies downgraded SolarEdge's stock from Hold to Underperform, citing a subdued outlook in Europe and strong competition. Meanwhile, Mizuho Securities lowered their price target for the company due to concerns over margin recovery and inventory levels, but maintained an Outperform rating.
Furthermore, SolarEdge's management structure has seen significant changes, with former CEO Zvi Lando stepping down and ex-CFO Ronen Faier stepping in as interim CEO. Ariel Porat, previously Senior VP of Finance, has assumed the CFO role.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on SolarEdge Technologies' current financial situation, aligning with RBC Capital's cautious outlook. The company's market capitalization stands at $1.07 billion, reflecting the significant challenges it faces.
InvestingPro Tips highlight that SolarEdge is "quickly burning through cash" and "suffers from weak gross profit margins," which corroborates the analyst's concerns about the company's near-term performance. The gross profit margin for the last twelve months as of Q2 2024 was a mere 7.82%, underscoring the pressure on profitability.
Moreover, the company's revenue growth has sharply declined, with a -58.74% decrease in the last twelve months as of Q2 2024. This aligns with the InvestingPro Tip that "analysts anticipate sales decline in the current year," further supporting RBC's decision to lower the price target.
It's worth noting that SolarEdge's stock price has fallen significantly, with a one-year price total return of -84.28% as of the latest data. This dramatic decline reflects the market's reaction to the company's challenges, including the competitive pressures mentioned in the RBC analysis.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for SolarEdge Technologies, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.